甲状腺乳头状癌中SMOC2的表达与临床病理意义  

Expression of SMOC2 in papillary thyroid carcinoma and its clinicopathological significance

作　　者：凡龙云 彭薇 王美玲 赵雅丽 肖寒 王万祥 吴强[1,3] 王弦[1,3] FAN Longyun;PENG Wei;WANG Meiling;ZHAO Yali;XIAO Han;WANG Wanxiang;WU Qiang;WANG Xian(Department of Pathology,the Second Affiliated Hospital of Anhui Medical University,Hefei 230601,China;Department of Pathology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China;Department of Pathology,Anhui Medical University,Hefei 230032,China)

机构地区：[1]安徽医科大学第二附属医院病理科,合肥230601 [2]安徽医科大学第一附属医院病理科,合肥230022 [3]安徽医科大学基础医学院病理学教研室,合肥230032

出　　处：《临床与实验病理学杂志》2023年第12期1492-1496,1502,共6页Chinese Journal of Clinical and Experimental Pathology

基　　金：安徽省高校优秀青年人才支持计划项目(gxyq2021177);安徽省高校自然科学研究重点项目(KJ2020A0183);安徽医科大学第二附属医院临床研究培育计划(2021LCYB02)。

摘　　要：目的探讨SMOC2在甲状腺乳头状癌(papillary thyroid carcinomas,PTC)中的表达及其与CK19、Galectin-3、MC和BRAF V600E联合辅助诊断的效能。方法采用生物信息技术学分析Gene Expression Omnibus数据库及The Cancer Genome Atlas数据库中SMOC2在PTC和良性甲状腺组织中的mRNA表达量差异;采用免疫组化EnVision法检测75例PTC和45例甲状腺乳头状增生(papillary thyroid hyperplasia,PTH)石蜡切片中SMOC2蛋白的表达,并分析其联合CK19、Galectin-3、MC和BRAF V600E进行辅助诊断的敏感度、特异性。结果生物信息学分析结果显示:SMOC2在PTC组织中的mRNA表达量显著低于良性甲状腺组织(P<0.05),且SMOC2对PTC诊断预测的曲线下面积(area under the curve,AUC)为0.910(P<0.001)。免疫组化结果显示:SMOC2在PTC中的表达显著低于PTH组织(P<0.001),且SMOC2对PTC诊断预测的AUC为0.898(P<0.001)。SMOC2与CK19、Galectin-3、MC和BRAF V600E五者联合辅助诊断PTC时的AUC为1.000(P<0.001),其余标志物相互组合时AUC值均低于1.000。结论SMOC2在PTC中的表达明显降低,可作为PTC诊断和鉴别诊断的重要标志物,与CK19、Galectin-3、MC和BRAF V600E五者联合辅助诊断PTC时可在一定程度上提高灵敏度和特异性。Purpose To investigate the expression of SMOC2 in papillary thyroid carcinomas(PTC)and its efficacy in joint diagnosis with CK19,Galectin-3,MC and BRAF V600E.Methods Bioinformatics was uesd to analyze the mRNA expression differences of SMOC2 in PTC and benign thyroid tissues in the Gene Expression Omnibus database and The Cancer Genome Atlas database.Detection of SMOC2 protein expression in paraffin tissue of 75 cases of PTC and 45 cases of papillary thyroid hyperplasia(PTH)was used by using EnVision method,combined with CK19,Galectin-3,and MC and BRAF V600E for sensitivity and specificity analysis.Results The bioinformatics analysis results showed that the mRNA expression level of SMOC2 in PTC tissue was significantly lower than that in benign thyroid tissue(P<0.05),and the area under the curve(AUC)predicted by SMOC2 for PTC diagnosis was 0.910(P<0.001).The immunohistochemical results showed that the expression of SMOC2 in PTC was significantly lower than that in PTH tissue(P<0.001),and the AUC of SMOC2 for PTC diagnosis was 0.898(P<0.001).The AUC of SMOC2 combined with CK19,Galectin-3,MC and BRAF V600E in the diagnosis of PTC was 1.000(P<0.001),and the AUC values of the combination of other markers were lower than 1.000.Conclusion The expression of SMOC2 in PTC is significantly decreased,which can be used as an important marker for the diagnosis and differential diagnosis of PTC.Combined with CK19,Galectin-3,MC and BRAF V600E,the sensitivity and specificity of PTC can be improved to a certain extent.

关 键 词：甲状腺肿瘤 甲状腺乳头状癌 乳头状增生 SMOC2 

分 类 号：R736.1[医药卫生—肿瘤]